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ABSTRACT We have independently isolated and charac-
terized cDNA and genomic clones for the human coagulation
factor IX. Sequence analysis in both cases indicates that
threonine is encoded by the triplet ACT as the third residue of
the activation peptide. This is in agreement with some earlier
reports but in disagreement with others that show the alanine
triplet GCT at this position. The discrepancy can thus be
accounted for by natural variation of a single nucleotide in the
normal population. Amino acid sequence analyses of activated
factor IX from plasma samples of four individuals yielded two
cases of alanine and two cases of threonine at the third position
of the activation peptide. In factor IX from pooled plasma and
in factor IX from a heterozygous individual, however, both
alanine and threonine were found. Taken together, the findings
show that a prevalent nondeleterious dimorphism exists in the
activation peptide of human coagulation factor IX.
Factor IX is the plasma protein that is missing or defective in
individuals afflicted with the X-chromosome-linked bleeding
disorder hemophilia B. Its role in the blood coagulation
cascade is to activate factor X through interactions with
calcium, membrane phospholipids, and factor VIII. Factor
IX circulates as an inactive zymogen until proteolytic release
of its "activation peptide" allows it to assume the conforma-
tion of an active serine protease.
At the molecular level, it is known that hemophilia B may
result from a variety of genetic changes (1, 2). Partial and/or
complete deletions of the factor IX gene have been shown to
be responsible for the disease in some cases (3, 4). Several
hemophilia B variants have also been described that show
normal levels of the factor IX protein by immunological
methods but have reduced or negligible activity in clotting
assays. These variants have been designated CRM+ (cross-
reacting material positive). One of the CRM+ variants, factor
IX Chapel Hill, results from an amino acid substitution at one of
the proteolytic activation sites, blocking cleavage and sub-
sequent activation (5). A change affecting the other cleavage
site is likely to be involved in the variant factor IXDeventer (6).
The molecular defect in another CRM+ variant, factor
IXAlabama (7), is presently under study in our laboratories. The
dimorphism described in this report, however, appears to be
the result of a nondeleterious mutation which has been fixed
in the normal population.
As early as 1978, a partial amino acid sequence was
reported for the amino-terminal region of the activation
peptide of human factor IX (8). This analysis, apparently
done on material from pooled plasma, showed an amino-
terminal sequence Ala-Glu-Thr-Val-Phe- for the activation
peptide, in agreement with a previously determined sequence
for the corresponding region from bovine factor IX (9). No
mention was made of alanine at the third position. Several
years later, however, the same laboratory did report a cDNA
sequence for human factor IX which indicated the presence
of an alanine codon at the third position of the sequence
encoding the activation peptide (10).
More recently, other reports based on DNA sequence
analysis of cDNA and genomic clones for human factor IX
have appeared. In two instances, alanine codons were found
for the third position of the activation peptide (11), agreeing
with the earlier report. In two other cases, however, threo-
nine codons were reported (12, 13). Here, based on DNA
sequence analysis of independently derived factor IX clones,
we report two additional occurrences of the threonine codon
at this position. These findings strongly suggest the existence
of a prevalent dimorphism at this site in the general popula-
tion. We further substantiate this observation by direct amino
acid sequence analysis of factor IX activation peptide derived
from individual and pooled plasmas. The findings may have
some implications for carrier detection and prenatal diagnosis
of disorders related to factor IX.
MATERIALS AND METHODS
Molecular Cloning. A human liver cDNA library was
constructed in the X phage vector gtlO and was screened for
factor IX clones by hybridization with end-labeled oligo-
nucleotide probes. Oligonucleotides were synthesized manu-
ally by a solid-phase triester method (14). The first cDNA
clone was detected by using a unique-sequence 18-mer probe
directed against the highly conserved active-site region
surrounding serine-365. The clone contained an insert of
approximately 200 base pairs (bp), which was recloned in
M13mp8 (15) and sequenced by the Sanger dideoxy method
(16). This clone was then used as probe to obtain a more
complete cDNA from a plasmid library (17) kindly provided
by S. Orkin. A factor IX cDNA of approximately 2.8 kilobase
pairs (kb) was obtained.
Genomic factor IX clones were obtained from a recombi-
nant library made with the DNA from a CRM+ hemophilia B
patient with the variant protein factor IXAlabama. The library
was prepared by partial digestion of genomic DNA with
EcoRI, size-selection, and ligation into the phage vector
XGT-XB. Several positive clones were selected initially with
oligonucleotide probes. From these, genuine factor IX clones
were identified by hybridization with cDNA. A complete
description of the cloning and characterization of the factor
IXAlabama gene will appear in a separate report.
DNA Sequencing. The entire 2.8-kb cDNA and exon
regions of the genomic DNA clones were sequenced by a
modification of the dideoxy method in which 5' end-labeled
oligonucleotide primers were used as the only source of
radiolabel (18). Primers were labeled with [y-32P]ATP (ICN
Abbreviations: bp, base pair(s); kb, kilobase pair(s).
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FIG. 1. Human factor IX cDNA sequence. The 2775-nucleotides sequence corresponds to the entire coding region and an extensive 3'
nontranslated sequence. Numbers above the sequence refer to nucleotide positions, and numbers below refer to amino acids. Numbering is
relative to the amino-terminal tyrosine (position 1) of the circulating zymogen. Three potential initiating methionine codons are underlined. Open
circles mark glutamic acid residues that are y-carboxylated in the mature protein; 8 indicates an aspartic acid residue that is B3-hydroxylated.
The activation peptide is enclosed with dashed lines. Closed circles mark three residues normally associated with the active site in serine
proteases. Sites differing from the sequence reported by Anson et al. (11) are indicated by diamonds. The difference at nucleotide 442 (within
the activation peptide) is shown in this report to represent a true dimorphism.
crude, >7000 Ci/mmol; 1 Ci = 37 GBq) and polynucleotide on linearized double-stranded DNA with various factor
kinase (P-L Biochemicals). The identity of the 2.8-kb factor IX-specific oligonucleotide probes. The remainder of the
IX cDNA clone was established initially by priming directly cDNA sequence was obtained with end-labeled universal
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primer (New England Biolabs) on single-stranded (M13)
templates generated either by the random sonication method
of Deininger (19) or by directed cloning. Sequences in the
exon regions of genomic clones were obtained similarly.
Amino Acid Sequence Analysis. Factor IX was obtained
from several sources. The factor IX concentrate, estimated to
represent a pool of as many as 1000 donors, was a gift from
F. Ofosu (Canadian Red Cross). Two of the individual plasma
donors were myasthenia gravis patients receiving plasma-
pheresis therapy. Three of the individual donors were male
patients with CRM' hemophilia B. Factor IX was purified by
methods adapted from DiScipio et al. (20) and Pepper and
Prowse (21) and was activated by treatment with either fac-
tor XIa, or Russell viper venom, or trypsin (33), and the
amino-terminal sequences of the resulting peptides were
determined.
Automated Edman degradation (22) was performed with a
Beckman 890C sequencer with a 0.1 M Quadrol program (23).
Phenylthiohydantoin amino acid derivatives were identified
by HPLC (24).
RESULTS AND DISCUSSION
DNA Sequence Analysis. More than 90% of the sequence
was obtained from both strands. The bulk of the sequence
was further confirmed by sequencing of additional templates.
The sequence of the 2775-nucleotide cDNA, roughly half of
which represents an extensive 3' nontranslated region of the
mRNA, is given in Fig. 1. All but the 15 nucleotides at the
extreme 5' end of the cDNA were determined from a single
cDNA clone. To our knowledge, this represents the most
extensive individual cDNA for human factor IX that has been
reported. Sequence at the extreme 5' end was obtained from
a second, smaller cDNA. Anson et al. (11) recently reported
that the mRNA start site lies 30 nucleotides upstream from
the first methionine codon shown here; this also was inferred
from genomic sequence by primer-extension and nuclease S1
analysis. In no case has the 5' end of the factor IX mRNA
actually been represented in a cDNA clone.
A schematic representation of the steps leading to deter-
mination of the genomic DNA sequence in the region of the
activation peptide is shown in Fig. 2. The sixth exon contains
the region of interest and encodes, in addition to the entire
activation peptide, flanking peptide sequences at either end.
The sequence of exon 6 is in complete agreement with the
cDNA sequence (nucleotides 383-585, Fig. 1).
Although comparison of the first two cDNA reports for
human factor IX (10, 12) revealed six differences, all but one
of these have apparently been resolved as sequencing errors
(11, 25). The single remaining difference has held up and, as
we show, reflects a true natural variation in the normal
population. The cDNA sequence reported here agrees with
that of Jaye et al. (12) throughout the coding region and
differs from the coding sequences reported by Anson et al.
(11) for cDNA and genomic clones and from the corrected
sequence of Davie and co-workers (ref. 25; cf. ref. 10) for
cDNA only at nucleotide 442, the first nucleotide of the triplet
encoding the third residue of the activation peptide (residue
148 of the zymogen). Since our genomic sequence in this
region matches our cDNA, there are now four reports with
threonine at this position and three with alanine (Fig. 3).
Interestingly, two of the cDNA clones differing at this
position were obtained from the same cDNA library (10, 13,
26). Further comparison of our sequence with that of Anson
et al. (11) reveals two other apparent single-base substitu-
tions in the 3' nontranslated region (see Fig. 1). Whether or
not these represent actual point differences in the normal
population will require corroboration at the nucleotide se-
quence level, since they lie in a nontranslated region. We are
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FIG. 2. Steps leading to determination ofgenomic DNA sequence
in the region of the activation peptide. (a) A genomic clone of 14 kb,
designated LC-7, was obtained by hybridization first with a synthetic
18-mer and then with factor IX cDNA. (b) A 7.1-kb EcoRI fragment
containing exon 6 was subcloned in the plasmid vector pUC9. (c) An
EcoRI/Sst I fragment of 468 bp was then force-cloned in the M13
vectors mplO and mphl. (d) Sequence was obtained from each end
of the fragment by priming with end-labeled universal primer. The
conlplete sequence of the 203-nucleotide exon was determined,
including the region that encodes the activation peptide. Scale is
approximate. R, EcoRI; S, Sst I. Exons are indicated by shaded
boxes. Solid vertical arrows indicate boundaries of the activation
peptide region within exon 6. The open arrow indicates the location
of the dimorphic site.
sequence of our cDNA clone, since clear sequence-gel
readings were obtained from both strands for this region.
Both of these differences (at nucleotides 1942 and 2187) have
been confirmed by sequencing the corresponding regions in
one of our genomic clones. In the report by Anson et al. (11),
the sequence for the 3' nontranslated region of their cDNA
was not confirmed in this way. Our sequence also indicates
that polyadenylylation of the mRNA occurs at the uridylate
corresponding to nucleotide 2637 rather than at nucleotide
2635.
There are four differences between our sequence and the
partial sequence reported by Jaye et al. (12) for the 3'
nontranslated region. Based on our experience, we suspect
that these differences may be due to reading errors at the
extreme 3' end of a sequencing film.
With regard to sequencing methodology, it may be ob-
served that all of the sequences in three reports (10, 11, 13)
and most of the sequences in another report (12) were
obtained by the chemical degradation method of Maxam and
Gilbert (27). Our DNA sequences were obtained entirely by


















FIG. 3. Dimorphism in the activation peptide of human factor IX.
Natural variation of a single nucleotide results in a nondeleterious
amino acid substitution that is apparently widespread in the normal
population. Nucleotide and amino acid sequence are shown in the
region of the dimorphism. Numbers refer to amino acid position
relative to the amino terminus of the circulating zymogen. Sequence
a was reported from amino acid sequence analysis (8), from cDNA
sequence by others (12, 13), and by ourselves from independently
derived cDNA and genomic clones. Sequence b was reported from
cDNA (10) and from cDNA and genomic clones (11).
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oligonucleotide primers. The general agreement of our se-
quences with those obtained by the Maxam-Gilbert tech-
nique supports the validity of our approach and suggests that
errors arising from the propagation of M13 phages or other-
wise inherent in the enzymatic method are rare.
Amino Acid Sequence Analysis. Results of the amino acid
sequence analysis offactor IX activation peptide from pooled
plasma and from five individuals are presented in Table 1.
These results support our observation that the dimorphism in
the activation peptide is prevalent. Two of the individuals
showed only threonine at the third cycle, and two showed
only alanine. The fact that three of the individuals are CRM'
hemophilia B patients is of no consequence here, since both
sequences in the region shown are present in normal as well
as hemophiliac individuals. The sequence from one indi-
vidual showed both threonine and alanine at the third cycle.
This is expected in a heterozygous female. Similarly, se-
quence analysis of the pooled sample also revealed both
threonine and alanine at the third cycle, a consequence of
heterogeneity at this site in the normal population.
Because the phenylthiohydantoin derivative ofthreonine is
partially degraded to the dehydrothreonine form, it is difficult
to quantitate threonine relative to the other phenylthiohy-
dantoin derivatives (28). In samples showing peaks for both
threonine and alanine at the third cycle, one can estimate
threonine based on the observed reduction in yield of alanine
at the third cycle relative to the first cycle. In the case of the
heterozygous individual, this gives a figure of roughly 40%
alanine at the third position, so roughly 60% threonine can be
inferred. In the case of the pooled material, the bias toward
threonine is even more pronounced, suggesting that the
threonine-coding allele is actually more prevalent in the
general population, perhaps by a ratio of as much as 4:1 over
the alanine allele. This helps to explain why a minor alanine
peak at this position may have been overlooked in an earlier
study (8).
Potential for Gene "Tracking." Taken together, the find-
ings presented here indicate the existence of a prevalent
dimorphism in the activation peptide of human coagulation
factor IX. This dimorphism has some potential for diagnostic
application in families at risk for factor IX-related disorders.
Through the use of synthetic oligonucleotide probes, it
should be possible to determine which alleles are represented
in a given individual (29-31). Alternatively, allele assign-
ments might be made by use of the extremely sensitive
gradient/denaturing gel system of Lerman et al. (32). In any
case, when the disorder can be shown to be associated with
Table 1. Amino-terminal sequence analysis for the activation
peptide region of factor IX from pooled plasma and
various individuals
Amino acid, nmol
Cycle 1 Cycle 2 Cycle 3 Cycle 4
Normal pool Ala, 0.56 Glu, 0.52 Ala, 0.10
Thr, NQ
Individual
Heterozygous Ala, 3.4 Glu, 3.5 Ala, 1.3 Val, 2.4
Thr, NQ
Factor IXNormal Ala, 1.7 Glu, 0.8 Thr, NQ
Factor IXAlabama Ala, 1.7 Glu, NQ Thr, NQ Val, 1.7
Factor lXthael Hill Ala, 0.22 Glu, 0.12 Ala, 0.19 Val, 0.22
Factor IXDeventer Ala, NQ Glu, NQ Ala, 0.08 Val, 0.09
The yields, in nmol, of phenthiohydantoin derivatives obtained in
the first three or four sequencing cycles are given. NQ, present but
not quantitated.
*Factor IXChapl Hill was activated with trypsin (33), yielding a peptide
with Leu-143 at its amino terminus. Results of cycles 4-7 are given
in this case.
a particular allele, carrier detection and prenatal diagnosis
become feasible. As in diagnosis based on restriction frag-
ment length polymorphisms (RFLPs), the success of this
approach depends on being able to demonstrate maternal
heterozygosity. If our estimate regarding the relative fre-
quencies of the two alleles is accurate, then roughly 30% of
females would be expected to be heterozygous for this
particular marker. In conjunction with RFLPs and other
point substitutions that may be identified, we should eventu-
ally be able to follow the factor IX gene in most families.
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